Rapp Report: The Prosecution of Doctors and Propaganda Campaign

The Prosecution of Doctors and Propaganda Campaign

https://therappreportpodcast.podbean.com/e/e18-the-prosecution-of-doctors-and-propaganda-campaign/

In this episode we discuss the witch hunt against pain doctors in the United States, particularly that of Dr. Steven Henson of Wichita, Kansas, who is now serving a life sentence. We also discuss the propaganda campaign being used against doctors and pain patients that fuels this opioid hysteria.

 

Rite Aid deployed facial recognition systems in hundreds of U.S. stores

Rite Aid deployed facial recognition systems in hundreds of U.S. stores

https://www.reuters.com/investigates/special-report/usa-riteaid-software/

In the hearts of New York and metro Los Angeles, Rite Aid installed facial recognition technology in largely lower-income, non-white neighborhoods, Reuters found. Among the technology the U.S. retailer used: a state-of-the-art system from a company with links to China and its authoritarian government.

Filed

Over about eight years, the American drugstore chain Rite Aid Corp quietly added facial recognition systems to 200 stores across the United States, in one of the largest rollouts of such technology among retailers in the country, a Reuters investigation found.

In the hearts of New York and metro Los Angeles, Rite Aid deployed the technology in largely lower-income, non-white neighborhoods, according to a Reuters analysis. And for more than a year, the retailer used state-of-the-art facial recognition technology from a company with links to China and its authoritarian government.

In telephone and email exchanges with Reuters since February, Rite Aid confirmed the existence and breadth of its facial recognition program. The retailer defended the technology’s use, saying it had nothing to do with race and was intended to deter theft and protect staff and customers from violence. Reuters found no evidence that Rite Aid’s data was sent to China.

Last week, however, after Reuters sent its findings to the retailer, Rite Aid said it had quit using its facial recognition software. It later said all the cameras had been turned off.

“This decision was in part based on a larger industry conversation,” the company told Reuters in a statement, adding that “other large technology companies seem to be scaling back or rethinking their efforts around facial recognition given increasing uncertainty around the technology’s utility.”

Reuters pieced together how the company’s initiative evolved, how the software has been used and how a recent vendor was linked to China, drawing on thousands of pages of internal documents from Rite Aid and its suppliers, as well as direct observations during store visits by Reuters journalists and interviews with more than 40 people familiar with the systems’ deployment. Most current and former employees spoke on condition of anonymity, saying they feared jeopardizing their careers.

While Rite Aid declined to disclose which locations used the technology, Reuters found facial recognition cameras at 33 of the 75 Rite Aid shops in Manhattan and the central Los Angeles metropolitan area during one or more visits from October through July.

The cameras were easily recognizable, hanging from the ceiling on poles near store entrances and in cosmetics aisles. Most were about half a foot long, rectangular and labeled either by their model, “iHD23,” or by a serial number including the vendor’s initials, “DC.” In a few stores, security personnel – known as loss prevention or asset protection agents – showed Reuters how they worked.

The cameras matched facial images of customers entering a store to those of people Rite Aid previously observed engaging in potential criminal activity, causing an alert to be sent to security agents’ smartphones. Agents then reviewed the match for accuracy and could tell the customer to leave.

Rite Aid told Reuters in a February statement that customers had been apprised of the technology through “signage” at the shops, as well as in a written policy posted this year on its website. Reporters found no notice of the surveillance in more than a third of the stores it visited with the facial recognition cameras.

Among the 75 stores Reuters visited, those in areas that were poorer or less white were much more likely to have the equipment, the news agency’s statistical analysis found.

Stores in more impoverished areas were nearly three times as likely as those in richer areas to have facial recognition cameras. Seventeen of 25 stores in poorer areas had the systems. In wealthier areas, it was 10 of 40. (Ten of the stores were in areas whose wealth status was not clear. Six of those stores had the equipment.)

In areas where people of color, including Black or Latino residents, made up the largest racial or ethnic group, Reuters found that stores were more than three times as likely to have the technology.

The Reuters findings illustrate “the dire need for a national conversation about privacy, consumer education, transparency, and the need to safeguard the Constitutional rights of Americans,” said Carolyn Maloney, the Democratic chairwoman of the House oversight committee, which has held hearings on the use of facial recognition technology.

Rite Aid said the rollout was “data-driven,” based on stores’ theft histories, local and national crime data and site infrastructure.

Cathy Langley, Rite Aid’s vice president of asset protection, said earlier this year that facial recognition – which she referred to as “feature matching” – resulted in less violence and organized crime in the company’s stores. Last week, however, Rite Aid said its new leadership team was reviewing practices across the company, and “this was one of a number of programs that was terminated.”

‘Orwellian surveillance’

Facial recognition technology has become highly controversial in the United States as its use has expanded in both the public and private sectors, including by law enforcement and retailers. Civil liberties advocates warn it can lead to harassment of innocent individuals, arbitrary and discriminatory arrests, infringements of privacy rights and chilled personal expression.

Adding to these concerns, recent research by a U.S. government institute showed that algorithms that underpin the technology erred more often when subjects had darker skin tones.

Facial recognition systems are largely unregulated in the United States, despite disclosure or consent requirements, or limits on government use, in several states, including California, Washington, Texas and Illinois. Some cities, including San Francisco, ban municipal officials from using them. In general, the technology makes photos and videos more readily searchable, allowing retailers almost instantaneous facial comparisons within and across stores.

Among the systems used by Rite Aid was one from DeepCam LLC, which worked with a firm in China whose largest outside investor is a Chinese government fund. Some security experts said any program with connections to China was troubling because it could open the door to aggressive surveillance in the United States more typical of an autocratic state.

U.S. Senator Marco Rubio, a Florida Republican and acting chair of the U.S. Senate’s intelligence committee, told Reuters in a statement that the Rite Aid system’s potential link to China was “outrageous.” “The Chinese Communist Party’s buildup of its Orwellian surveillance state is alarming, and China’s efforts to export its surveillance state to collect data in America would be an unacceptable, serious threat,” he said.

The security specialists expressed concern that information gathered by a China-linked company could ultimately land in that government’s hands, helping Beijing refine its facial recognition technology globally and monitor people in ways that violate American standards of privacy.

“If it goes back to China, there are no rules,” said James Lewis, the Technology Policy Program director at the Washington-based Center for Strategic and International Studies.

Asked for comment, China’s Ministry of Foreign Affairs said: “These are unfounded smears and rumors.”

‘A promising new tool’

Rite Aid, afflicted with financial losses in recent years, is not the only retailer to adopt or explore facial recognition technology.

Two years ago, the Loss Prevention Research Council, a coalition founded by retailers to test anti-crime techniques, called facial recognition “a promising new tool” worthy of evaluation.

“There are a handful of retailers that have made the decision, ‘Look, we need to leverage tech to sell more and lose less,” said council director Read Hayes. Rite Aid’s program was one of the largest, if not the largest, in retail, Hayes said. The Camp Hill, Pennsylvania-based company operates about 2,400 stores around the country.

The Home Depot Inc said it had been testing facial recognition to reduce shoplifting in at least one of its stores but stopped the trial this year. A smaller rival, Menards, piloted systems in at least 10 locations as of early 2019, a person familiar with that effort said.

Walmart Inc has also tried out facial recognition in a handful of stores, said two sources with knowledge of the tests. Walmart and Menards had no comment.

Using facial recognition to approach people who previously have committed “dishonest acts” in a store before they do so again is less dangerous for staff, said Rite Aid’s former vice president of asset protection, Bob Oberosler, who made the decision to deploy an early facial recognition system at Rite Aid. That way, “there was significantly less need for law enforcement involvement,” he said.

‘Tougher’ neighborhoods

In interviews, 10 current and former Rite Aid loss prevention agents told Reuters that the system they initially used in stores was from a company called FaceFirst, which has been backed by U.S. investment firms.

It regularly misidentified people, all 10 of them said.

“It doesn’t pick up Black people well,” one loss prevention staffer said last year while using FaceFirst at a Rite Aid in an African-American neighborhood of Detroit. “If your eyes are the same way, or if you’re wearing your headband like another person is wearing a headband, you’re going to get a hit.”

FaceFirst’s chief executive, Peter Trepp, said facial recognition generally works well irrespective of skin tone, an issue he said the industry addressed years ago. He declined to talk about Rite Aid, saying he would not discuss any possible clients.

Rite Aid originally piloted FaceFirst at its store on West 3rd Street and South Vermont Avenue in Los Angeles, a largely Asian and Latino neighborhood, around 2012.

 

Rapp Report: Cathy Kean, Chronic Pain Warrior

Cathy Kean, Chronic Pain Warrior

https://therappreportpodcast.podbean.com/e/e17-cathy-kean-chronic-pain-warrior/

In this episode, we interview Cathy Kean. Cathy is a chronic pain warrior and a very active and outspoken member of the chronic pain community. Not only does she deal with her own pain, but she advocates for others suffering from excruciating pain, and whose lives have been devastated by the opioid hysteria. In particular, she raises awareness of the thousands of people who have succumbed to their pain and taken their own lives.

Dr. Thomas Kline, MD, PhD: Medical Myths Revealed: THREATS OF TAPERING YOUR OPIATE PAIN MEDICINES? FIGHT BACK, IT IS MEDICAL MALPRACTICE and CRUEL

 

Even CDC says if you do want to taper, and then only if the medicine is not working or is causing serious side effects, you have to taper slowly at 10% a month! NEVER ABRUPTLY if doctors or pharmacists try to to do so, report them to the medical or pharmacy boards. This is only done in the United States where the government is so frightened of people with addiction disease they suggest a nihilist approach to pain. It is more important to stop new addictions, which have not increased since 1920 anyway. Wrong treatment “harming pain patients” as the AMA has said June 16, wrong problem

Dr. Thomas Kline, MD, PhD: Medical Myths Revealed: MORE ON AMA LETTER TO CDC SHREDDING THE GUIDELINES. TIME TO ACT – REPEAL THE GUIDELINES

Over the past 4 years the job of caring for people in pain has collapsed. Less that 20% of previously controlled long term rare painful diseases, 10 million all together, are still being treated. The agony and horror of living an adjusted but normal life taking opiate pain medicine to have the rug jerked out by fanatics at PROP/CDC suggesting 4000 years of pain medications have not worked and is so dangerous best not take them and get rid of them if already on them. The world was fine prior to March 15, 2016 when CDC improperly published these terrible “guidelines”, REPEAL before one more person’s life is ruined, before one more person ends their lives. Talk to your reps!

Masks: the cure could be worse than the disease

I have posted something like this before based and some came out of the “woodwork” and attempted to discredit me…. my experience with over ONE THOUSAND PTS using oxygen supplementation and the potential risk of people re-breathing the CO2 that they have just exhaled.  When you have a pt on nasal cannula their normal flow is 2 LPM (Liters per minute) but when you put a pt on a O2 MASK… you are required to increase their flow to 5-6 LPM for no other reason but to flush the mask they are using so that they don’t re-breathe the CO2 that they just exhaled.

CO2 is more dense/heavier than Oxygen… so if a person re-breathes the CO2 that they exhaled. it is possible for it to settle into the bottom of their lungs and blocking the alveoli which is the part of the lungs that assimilates the oxygen from the lungs into the arterial blood system.

So the person wearing a mask is at risk of developing hypoxia (Low oxygen saturated arterial blood).  This video demonstrates that within < one minute the CO2 within a mask is at dangerous levels.

Commit this to memory – it could save your life

Trump’s four executive orders to lower drug prices: What to know

Trump’s four executive orders to lower drug prices: What to know

https://www.foxbusiness.com/healthcare/trump-four-executive-orders-drug-prices

President Trump issued a handful of executive orders Friday that aim to lower prescription drug prices through a variety of methods, including allowing medications to be imported from other countries.

“I’m signing four sweeping executive orders that will lead to a massive reduction in drugs costs,” Trump said during a press briefing at the White House. “[The measures] will completely restore the prescription drug market in terms of prices.”

Trump claimed drug prices had fallen under his administration for the first time in more than five decades but added that he was determined to do more.

One of the orders introduced Friday would deliver rebates from drug companies directly to patients for insulin and Epipens in a bid to prevent providers from pocketing the discounts themselves while charging low-income patients unaffordable prices.

Trump said the price of insulin would come down to “pennies” per day.

The second order would allow wholesalers and pharmacies to legally import prescription drugs from Canada and other countries, where the president has repeatedly alleged identical drugs are available at costs as much as 90 percent lower than in the U.S.

The third order would bypass pharmacy benefit managers and other “middlemen” to deliver discounts for prescription drugs directly to patients. Trump said Friday that patients often never see these discounts from the manufacturer.

A final “favored nations” policy would require Medicare to purchase drugs at the same prices paid by foreign countries, which Trump said will prevent the U.S. from continuing to subsidize the cost of research and development for the entire world.

Medicare will leverage its purchasing power to negotiate prices – the goal would be to find a middle ground with other countries that allegedly pay less for the same prescription drugs.

This order will not be signed until the end of August, which would give the country’s largest companies time to come up with alternative solutions.

Ukrainians admit selling fakes of Merck’s Keytruda in US

Ukrainians admit selling fakes of Merck’s Keytruda in US

https://www.securingindustry.com/pharmaceuticals/ukrainians-admit-selling-fakes-of-merck-s-keytruda-in-us/s40/a12013/

Two Ukrainian men have admitted to selling counterfeit cancer drugs in the US, including knock-offs of Merck & Co’s big-selling cancer immunotherapy Keytruda.

Maksym Nienadov (36) – the owner of a Ukrainian company called Healthy Nation – and employee Volodymyr Nikolaienko (33) pleaded guilty to conspiracy, trafficking in counterfeit drugs and smuggling goods into the US. Nienadov also admitted to introducing misbranded drugs into the US market.

Along with Keytruda (pembrolizumab), the men also admitted unlawfully selling counterfeits of Bristol-Myers Squibb/Celgene’s cancer drug Abraxane (nab-paclitaxel) as well as Epclusa (sofosbuvir/velpatasvir), a treatment for hepatitis C virus marketed by Gilead Sciences.

US enforcement agencies started investigating the pair in 2018, spending thousands of dollars on test purchases of all three medicines that Nienadov and Nikolaienko were offering for sale.

On receipt of the products, the samples were sent to the drug manufacturers for testing, and the packages and contents of all of them were found to be counterfeit.

Nienadov and Nikolaienko were taken into custody in April 2019, after they arrived in the US from Ukraine “to discuss future unlawful shipments of pharmaceuticals,” according to a Department of Justice statement.

The two men are due to be sentenced on 4 November, it says.

The case is another example of counterfeiters falsifying high-value pharmaceutical products in the interest of making a quick profit, regardless of the consequences on people’s health.

Often, counterfeit medicines don’t contain the active ingredient promised on the label, and can also contain contaminants that can cause toxicity or infection – particularly in the case of drugs like Keytruda and Abraxane that are administered by intravenous infusion.

Keytruda is on course to become the top-selling drug in the world in the next few years, topping $11bn in sales last year and expected to top $14bn this year thanks to a steady stream of new approvals.

A few years ago, falsified cancer medicines hit the headlines after a notorious case in which fake copies of Roche’s antibody drug Avastin (bevacizumab) was purchased by nearly 100 US physicians and is thought to have been administered to patients.

I have read that a single treatment of Keytruda can run an insurance/pt upward of $13,000.   That has always seem to be a common denominator with fake meds found out in the marketplace …. the higher their wholesale cost … the more likely someone will try to create fake product and get it into the distribution system.

 

20 minutes of working at CVS/Pharmacy

20 minutes of working at CVS/Pharmacy